



Astec LifeSciences Ltd.

Date: 24th June, 2025

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: BSE Scrip Code No. “533138”

Ref.: “ASTEC”

Sub.: Outcome of the Meeting of the Board of Directors of Astec LifeSciences Limited (the “Company”) held on 24th June, 2025 and intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Dear Sir / Madam,

In continuation to our prior intimation dated 19th June, 2025, we wish to inform you that, the Board of Directors of the Company (the “**Board**”), at its Meeting held today, i.e., on Tuesday, 24th June, 2025, has, *inter alia*, considered and approved the issue of fully paid-up Equity Shares of the Company of face value of Rs. 10/- each (the “**Equity Shares**”) for an amount not exceeding Rs. 250 Crore (Rupees Two Hundred and Fifty Crore) by way of a Rights Issue to the eligible Equity Shareholders of the Company as on the record date (to be determined and notified subsequently, and such issue, the “**Rights Issue**”), in accordance with applicable laws, including the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the “**SEBI ICDR Regulations**”), as amended, subject to such regulatory and statutory approvals, as may be relevant under the applicable laws.

For the purposes of giving effect to the Rights Issue, the specific and detailed terms in relation to the Rights Issue, including but not limited to, the determination of the issue price, rights entitlement ratio, record date, timing of the rights issue and terms of payment will be determined by the Board and / or a duly constituted Committee of the Board of Directors authorized in this regard.

The Meeting of the Board commenced at 10.00 a.m. and concluded at 11.25 a.m.

This disclosure is made in terms of Regulation 30 read with Schedule III and other applicable provisions of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, as amended/updated from time to time.

We request you to please take the above information on your records.

The copy of the same is also being made available on the website of the Company i.e., <https://www.godrejastec.com/>.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236